| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
Experimental Therapeutics, Preclinical Pharmacology |
Gastrointestinal Oncology Research Laboratory, Division of Solid Tumor Oncology, Department of Medicine [M. M., C. J., M. A. S., G. K. S.], Program of Molecular Pharmacology and Experimental Therapeutics [F. M. S., Y. S.], and Department of Epidemiology and Biostatistics [M. G.], Memorial Sloan Kettering Cancer Center, New York, New York 10021
CPT-11, a DNA topoisomerase I inhibitor, has demonstrated clinical activity in colorectal cancer. Flavopiridol, a cyclin-dependent kinase inhibitor, is rapidly emerging as a chemotherapy modulator. To enhance the therapeutic index of CPT-11 in colon cancer, we studied the combination of these two drugs in relatively resistant human colon cancer cells, Hct116. Exposure of parental Hct116 cells to clinically achievable concentrations of SN-38 (the active metabolite of CPT-11) induces p21 and a G2 arrest. However, these conditions fail to induce apoptosis. In contrast, Hct116 cells that are p21 deficient (p21-/- Hct116) readily undergo apoptosis after treatment with SN-38. In this study we show that the parental Hct116 cells can be sensitized to undergo apoptosis by the addition of flavopiridol after SN-38 treatment. The induction of apoptosis was greatest with sequential therapy consisting of SN-38 followed by flavopiridol. Clonogenic assays also showed greatest inhibition with this sequence. Sequential treatment with SN-38 followed by flavopiridol was associated with higher activation of caspase-3 and greater cleavage of both p21 and XIAP, an inhibitor of apoptosis, compared with other treatment schedules. CPT-11 induced some tumor regressions but no complete responses in the p21-intact Hct116 xenografts. CPT-11 with flavopiridol more than doubled tumor regression, compared with CPT-11 alone, and produced a 30% complete response rate. Our studies indicate that CPT-11 induces cell cycle arrest rather than cell death and that flavopiridol, by activating the caspase cascade, cleaves the inhibitors of apoptosis and sensitizes the cells to undergo cell death. Thus, flavopiridol combined with CPT-11 may provide a completely new therapeutic approach in the treatment of colon cancer.
This article has been cited by other articles:
|
|
 |
|
  S. TORIGOE, Y. OGATA, K. MATONO, and K. SHIROUZU Molecular Mechanisms of Sequence-dependent Antitumor Effects of SN-38 and 5-Fluorouracil Combination Therapy against Colon Cancer Cells Anticancer Res, June 1, 2009; 29(6): 2083 - 2089. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. S. Nair, E. de Stanchina, and G. K. Schwartz The Topoisomerase I Poison CPT-11 Enhances the Effect of the Aurora B Kinase Inhibitor AZD1152 both In vitro and In vivo Clin. Cancer Res., March 15, 2009; 15(6): 2022 - 2030. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
W.-S. Hsieh, R. Soo, B.-K. Peh, T. Loh, D. Dong, D. Soh, L.-S. Wong, S. Green, J. Chiao, C.-Y. Cui, et al. Pharmacodynamic Effects of Seliciclib, an Orally Administered Cell Cycle Modulator, in Undifferentiated Nasopharyngeal Cancer Clin. Cancer Res., February 15, 2009; 15(4): 1435 - 1442. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. N. Tse, T. N. Sheikh, H. Alan, T.-C. Chou, and G. K. Schwartz 90-kDa Heat Shock Protein Inhibition Abrogates the Topoisomerase I Poison-Induced G2/M Checkpoint in p53-Null Tumor Cells by Depleting Chk1 and Wee1 Mol. Pharmacol., January 1, 2009; 75(1): 124 - 133. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 G. Ambrosini, S. L. Seelman, L.-X. Qin, and G. K. Schwartz The Cyclin-Dependent Kinase Inhibitor Flavopiridol Potentiates the Effects of Topoisomerase I Poisons by Suppressing Rad51 Expression in a p53-Dependent Manner Cancer Res., April 1, 2008; 68(7): 2312 - 2320. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
F. Perrone, S. Suardi, E. Pastore, P. Casieri, M. Orsenigo, S. Caramuta, G. Dagrada, M. Losa, L. Licitra, P. Bossi, et al. Molecular and Cytogenetic Subgroups of Oropharyngeal Squamous Cell Carcinoma. Clin. Cancer Res., November 15, 2006; 12(22): 6643 - 6651. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C. P. Fanton, M. W. Rowe, E. J. Moler, M. Ison-Dugenny, S. K. De Long, K. Rendahl, Y. Shao, T. Slabiak, T. G. Gesner, and M. L. MacKichan Development of a Screening Assay for Surrogate Markers of Chk1 Inhibitor-Induced Cell Cycle Release J Biomol Screen, October 1, 2006; 11(7): 792 - 806. [Abstract] [PDF]
|
|
|
|
 |
|
 G. I. Shapiro Cyclin-Dependent Kinase Pathways As Targets for Cancer Treatment J. Clin. Oncol., April 10, 2006; 24(11): 1770 - 1783. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
G. K. Schwartz and M. A. Shah Targeting the Cell Cycle: A New Approach to Cancer Therapy J. Clin. Oncol., December 20, 2005; 23(36): 9408 - 9421. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 X. Lu, J. i. Jung, H. J. Cho, D. Y. Lim, H. S. Lee, H. S. Chun, D. Y. Kwon, and J. H. Park Fisetin Inhibits the Activities of Cyclin-Dependent Kinases Leading to Cell Cycle Arrest in HT-29 Human Colon Cancer Cells J. Nutr., December 1, 2005; 135(12): 2884 - 2890. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
G. K. Schwartz Development of Cell Cycle Active Drugs for the Treatment of Gastrointestinal Cancers: A New Approach to Cancer Therapy J. Clin. Oncol., July 10, 2005; 23(20): 4499 - 4508. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. A. Shah, J. Kortmansky, M. Motwani, M. Drobnjak, M. Gonen, S. Yi, A. Weyerbacher, C. Cordon-Cardo, R. Lefkowitz, B. Brenner, et al. A Phase I Clinical Trial of the Sequential Combination of Irinotecan Followed by Flavopiridol Clin. Cancer Res., May 15, 2005; 11(10): 3836 - 3845. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. A. Shah, N. Kemeny, A. Hummer, M. Drobnjak, M. Motwani, C. Cordon-Cardo, M. Gonen, and G. K. Schwartz Drg1 Expression in 131 Colorectal Liver Metastases: Correlation with Clinical Variables and Patient Outcomes Clin. Cancer Res., May 1, 2005; 11(9): 3296 - 3302. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 H. G. Moore, J. Shia, D. S. Klimstra, L. Ruo, M. Mazumdar, G. K. Schwartz, B. D. Minsky, L. Saltz, and J. G. Guillem Expression of p27 in Residual Rectal Cancer after Preoperative Chemoradiation Predicts Long-term Outcome Ann. Surg. Oncol., November 1, 2004; 11(11): 955 - 961. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. N. Tse and G. K. Schwartz Potentiation of Cytotoxicity of Topoisomerase I Poison by Concurrent and Sequential Treatment with the Checkpoint Inhibitor UCN-01 Involves Disparate Mechanisms Resulting in Either p53-Independent Clonogenic Suppression or p53-Dependent Mitotic Catastrophe Cancer Res., September 15, 2004; 64(18): 6635 - 6644. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
Z. N. Demidenko and M. V. Blagosklonny Flavopiridol Induces p53 via Initial Inhibition of Mdm2 and p21 and, Independently of p53, Sensitizes Apoptosis-Reluctant Cells to Tumor Necrosis Factor Cancer Res., May 15, 2004; 64(10): 3653 - 3660. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R. I. Fisher, T. P. Miller, and O. A. O'Connor Diffuse Aggressive Lymphoma Hematology, January 1, 2004; 2004(1): 221 - 236. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. Jung, M. Motwani, J. Kortmansky, F. M. Sirotnak, Y. She, M. Gonen, A. Haimovitz-Friedman, and G. K. Schwartz The Cyclin-Dependent Kinase Inhibitor Flavopiridol Potentiates {gamma}-Irradiation-Induced Apoptosis in Colon and Gastric Cancer Cells Clin. Cancer Res., December 1, 2003; 9(16): 6052 - 6061. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. Jiang, C. B. Matranga, D. Cai, V. M. Latham Jr., X. Zhang, A. M. Lowell, F. Martelli, and G. I. Shapiro Flavopiridol-Induced Apoptosis during S Phase Requires E2F-1 and Inhibition of Cyclin A-Dependent Kinase Activity Cancer Res., November 1, 2003; 63(21): 7410 - 7422. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. Aklilu, H. L. Kindler, R. C. Donehower, S. Mani, and E. E. Vokes Phase II study of flavopiridol in patients with advanced colorectal cancer Ann. Onc., August 1, 2003; 14(8): 1270 - 1273. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. A. Shabbits, Y. Hu, and L. D. Mayer Tumor Chemosensitization Strategies Based on Apoptosis Manipulations Mol. Cancer Ther., August 1, 2003; 2(8): 805 - 813. [Full Text] [PDF]
|
|
|
|
|
|
M. Motwani, C. Rizzo, F. Sirotnak, Y. She, and G. K. Schwartz Flavopiridol Enhances the Effect of Docetaxel in Vitro and in Vivo in Human Gastric Cancer Cells Mol. Cancer Ther., June 1, 2003; 2(6): 549 - 555. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. T. Kouroukis, A. Belch, M. Crump, E. Eisenhauer, R. D. Gascoyne, R. Meyer, R. Lohmann, P. Lopez, J. Powers, R. Turner, et al. Flavopiridol in Untreated or Relapsed Mantle-Cell Lymphoma: Results of a Phase II Study of the National Cancer Institute of Canada Clinical Trials Group J. Clin. Oncol., May 1, 2003; 21(9): 1740 - 1745. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. Wittmann, P. Bali, S. Donapaty, R. Nimmanapalli, F. Guo, H. Yamaguchi, M. Huang, R. Jove, H. G. Wang, and K. Bhalla Flavopiridol Down-Regulates Antiapoptotic Proteins and Sensitizes Human Breast Cancer Cells to Epothilone B-induced Apoptosis Cancer Res., January 1, 2003; 63(1): 93 - 99. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Motwani, F. M. Sirotnak, Y. She, T. Commes, and G. K. Schwartz Drg1, a Novel Target for Modulating Sensitivity to CPT-11 in Colon Cancer Cells Cancer Res., July 15, 2002; 62(14): 3950 - 3955. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
G. K. Schwartz, E. O'Reilly, D. Ilson, L. Saltz, S. Sharma, W. Tong, P. Maslak, M. Stoltz, L. Eden, P. Perkins, et al. Phase I Study of the Cyclin-Dependent Kinase Inhibitor Flavopiridol in Combination With Paclitaxel in Patients With Advanced Solid Tumors J. Clin. Oncol., April 15, 2002; 20(8): 2157 - 2170. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. B. Matranga and G. I. Shapiro Selective Sensitization of Transformed Cells to Flavopiridol-induced Apoptosis following Recruitment to S-Phase Cancer Res., March 1, 2002; 62(6): 1707 - 1717. [Abstract] [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| Cancer Research | Clinical Cancer Research |
| Cancer Epidemiology Biomarkers & Prevention | Molecular Cancer Therapeutics |
| Molecular Cancer Research | Cancer Prevention Research |
| Cancer Prevention Journals Portal | Cancer Reviews Online |
| Annual Meeting Education Book | Meeting Abstracts Online |
